FindTrial
Sign In

Prospective cohort study on the preventive effect of ornithine aspartate on hepatic encephalopathy in patients with liver cirrhosis

Prospective cohort study on the preventive effect of ornithine aspartate on hepatic encephalopathy in patients with liver cirrhosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118662
Enrollment
Unknown
Registered
2026-02-09
Start date
2026-02-09
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic Encephalopathy

Interventions

Lola treated group:None
No Lola treatment group:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-75 2.Cirrhosis (child Pugh a/b/c) 3.Baseline blood ammonia exceeds the upper limit of normal 4.Signed informed consent 5. Voluntarily participate in the study and promise to cooperate to complete the follow-up.

Exclusion criteria

Exclusion criteria: 1. Previous dominant he (West Haven grade II or above) 2. Active gastrointestinal bleeding within 6 months 3. Liver / kidney transplantation 4. Lola allergy history 5. Expected survival <6 months

Design outcomes

Primary

MeasureTime frame
Blood ammonia;Safety index;Sychometric Hepatic Encephalopathy Score;Alanine Aminotransferase;Aspartate Aminotransferase;?-Glutamyl Transferase;Albumin;Bilirubin;—

Countries

China

Contacts

Public ContactEnqiang Chen

West China Hospital, Sichuan University

chenenqiang1983@hotmail.com+86 189 8060 6517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026